Vaccibody CEO Bonde: Make Undefeatable Diseases Defeatable
This article was originally published in Scrip
Executive Summary
Norway-based vaccine company, Vaccibody, has recently begun the first stage of clinical trials with its immunotherapy VB10.16 for patients with cervical intraepithelial neoplasia (CIN 2/3). Dr. Martin Bonde, a biotech veteran who sold EpiTherapeutics ApS to Gilead Sciences Inc. earlier this year for $65m, is now its CEO. He tells Scrip about his new challenge to use Vaccibody's unique technology to treat CIN and make undefeatable diseases defeatable.
You may also be interested in...
Venture Funding Deals: Takeda Ups Its Bet On Immuno-Oncology Play Maverick
Biscayne and Japanese CRO SNBL create spin-outs to advance programs; liver disease specialist Ascletis gains funds as it shifts away from HCV; Neon gets $100m to put into its cancer vaccines; and other highlights of recent VC funding.
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.